Published in J Mater Sci Mater Med on April 03, 2011
New Tools in Experimental Cellular Therapy for the Treatment of Liver Diseases. Curr Transplant Rep (2015) 0.77
Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell (2006) 120.51
Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell (2007) 101.42
Induced pluripotent stem cell lines derived from human somatic cells. Science (2007) 71.50
Generation of germline-competent induced pluripotent stem cells. Nature (2007) 32.77
Reprogramming of human somatic cells to pluripotency with defined factors. Nature (2007) 30.84
In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature (2007) 28.24
Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol (2007) 21.93
Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc Natl Acad Sci U S A (2008) 13.09
Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol (2008) 10.29
Efficient differentiation of human embryonic stem cells to definitive endoderm. Nat Biotechnol (2005) 9.58
Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. Nature (2008) 7.07
Oct4-induced pluripotency in adult neural stem cells. Cell (2009) 6.50
Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation (2003) 6.30
Generation of human-induced pluripotent stem cells. Nat Protoc (2008) 4.85
Reprogramming of murine and human somatic cells using a single polycistronic vector. Proc Natl Acad Sci U S A (2008) 4.48
Reprogramming of fibroblasts into induced pluripotent stem cells with orphan nuclear receptor Esrrb. Nat Cell Biol (2009) 4.32
Human hepatic stem cells from fetal and postnatal donors. J Exp Med (2007) 4.15
Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J Clin Invest (2002) 3.90
Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. N Engl J Med (1998) 3.77
Generation of functional human hepatic endoderm from human induced pluripotent stem cells. Hepatology (2010) 3.36
Highly efficient differentiation of hESCs to functional hepatic endoderm requires ActivinA and Wnt3a signaling. Proc Natl Acad Sci U S A (2008) 2.99
The phenotypes of pluripotent human hepatic progenitors. Stem Cells (2006) 2.41
Hepatocyte differentiation of mesenchymal stem cells from human adipose tissue in vitro promotes hepatic integration in vivo. Gut (2008) 2.32
Efficient differentiation of functional hepatocytes from human embryonic stem cells. Stem Cells (2008) 2.29
Molecular basis of transdifferentiation of pancreas to liver. Nat Cell Biol (2000) 2.29
Efficient differentiation of hepatocytes from human embryonic stem cells exhibiting markers recapitulating liver development in vivo. Stem Cells (2008) 2.20
Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes. Hepatology (2007) 2.14
Challenges with advanced therapy medicinal products and how to meet them. Nat Rev Drug Discov (2010) 2.09
FDA regulation of stem-cell-based therapies. N Engl J Med (2006) 2.01
Controlling cell interactions by micropatterning in co-cultures: hepatocytes and 3T3 fibroblasts. J Biomed Mater Res (1997) 2.00
Functional integration of hepatocytes derived from human mesenchymal stem cells into mouse livers. Gut (2006) 1.96
A microfabricated array bioreactor for perfused 3D liver culture. Biotechnol Bioeng (2002) 1.87
Hepatocyte transplantation as a treatment for glycogen storage disease type 1a. Lancet (2002) 1.86
Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg (2004) 1.79
Hepatocyte transplantation as a bridge to orthotopic liver transplantation in terminal liver failure. Transplantation (1997) 1.67
Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review. JAMA (2003) 1.62
Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology (1996) 1.57
Hepatocyte transplantation for the treatment of human disease. Semin Liver Dis (1999) 1.57
Human fetal hepatocyte transplantation in patients with fulminant hepatic failure. Transplantation (1994) 1.54
Generation and characterization of human induced pluripotent stem cells. Curr Protoc Stem Cell Biol (2009) 1.50
Isolated hepatocyte transplantation in an infant with a severe urea cycle disorder. Pediatrics (2003) 1.49
Treatment of cirrhosis and liver failure in rats by hepatocyte xenotransplantation. Gastroenterology (2003) 1.48
Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. Ann Surg (1997) 1.38
Stem cells in liver regeneration, fibrosis and cancer: the good, the bad and the ugly. J Pathol (2009) 1.35
Hepatocyte transplantation in a 4-year-old girl with peroxisomal biogenesis disease: technique, safety, and metabolic follow-up. Transplantation (2003) 1.31
Survival and function of hepatocytes on a novel three-dimensional synthetic biodegradable polymer scaffold with an intrinsic network of channels. Ann Surg (1998) 1.29
Reversal of fulminant hepatic failure using an extracorporeal liver assist device. Hepatology (1992) 1.26
Differentiation of in vitro-modified human peripheral blood monocytes into hepatocyte-like and pancreatic islet-like cells. Gastroenterology (2005) 1.26
Typical pitfalls in applications for marketing authorization of biotechnological products in Europe. Nat Rev Drug Discov (2008) 1.26
Clinical application of bioartificial liver support systems. Ann Surg (2004) 1.24
Stem cells in gastroenterology and hepatology. Nat Rev Gastroenterol Hepatol (2009) 1.23
Microanatomy of the human liver-exploring the hidden interfaces. Hepatology (1999) 1.22
Porcine endogenous retroviruses: no infection in patients treated with a bioreactor based on porcine liver cells. J Clin Virol (2003) 1.20
Umbilical-cord blood transplantation for the treatment of cancer. Nat Rev Cancer (2003) 1.18
Time course of primary liver cell reorganization in three-dimensional high-density bioreactors for extracorporeal liver support: an immunohistochemical and ultrastructural study. Tissue Eng (2004) 1.18
Hepatic tissue engineering: from transplantation to customized cell-based liver directed therapies from the laboratory. J Cell Mol Med (2007) 1.18
Treatment of liver failure in rats with end-stage cirrhosis by transplantation of immortalized hepatocytes. Hepatology (2002) 1.18
Hepatocyte transplantation for inherited factor VII deficiency. Transplantation (2004) 1.18
Adult-derived human liver mesenchymal-like cells as a potential progenitor reservoir of hepatocytes? Cell Transplant (2007) 1.17
Functional behavior of primary rat liver cells in a three-dimensional perfused microarray bioreactor. Tissue Eng (2002) 1.16
Charitable State-Controlled Foundation Human Tissue and Cell Research: Ethic and Legal Aspects in the Supply of Surgically Removed Human Tissue For Research in the Academic and Commercial Sector in Germany. Cell Tissue Bank (2003) 1.16
Human skin fibroblasts: From mesodermal to hepatocyte-like differentiation. Hepatology (2007) 1.15
Hepatic differentiation induced by oncostatin M attenuates fetal liver hematopoiesis. Proc Natl Acad Sci U S A (1999) 1.13
Isolated hepatocyte transplantation for Crigler-Najjar syndrome type 1. Cell Transplant (2005) 1.12
Tissue engineering and reparative medicine. Ann N Y Acad Sci (2002) 1.12
Stem and progenitor cells for liver repopulation: can we standardise the process from bench to bedside? Gut (2008) 1.12
In vitro evaluation of a novel bioreactor based on an integral oxygenator and a spirally wound nonwoven polyester matrix for hepatocyte culture as small aggregates. J Hepatol (1997) 1.11
Use of primary human liver cells originating from discarded grafts in a bioreactor for liver support therapy and the prospects of culturing adult liver stem cells in bioreactors: a morphologic study. Transplantation (2003) 1.08
Morphological mechanisms for regulating blood flow through hepatic sinusoids. Liver (2000) 1.07
Concise review: mind the gap: challenges in characterizing and quantifying cell- and tissue-based therapies for clinical translation. Stem Cells (2010) 1.04
Hepatic tissue engineering for adjunct and temporary liver support: critical technologies. Liver Transpl (2004) 1.04
Phase I clinical trial with the AMC-bioartificial liver. Int J Artif Organs (2002) 1.04
A novel full-scale flat membrane bioreactor utilizing porcine hepatocytes: cell viability and tissue-specific functions. Biotechnol Prog (2000) 1.02
Hepatic stem/progenitor cells and stem-cell transplantation for the treatment of liver disease. J Gastroenterol (2009) 1.02
Clonal expansion of adult rat hepatic stem cell lines by suppression of asymmetric cell kinetics (SACK). Biotechnol Bioeng (2003) 1.01
Which hepatocyte will it be? Hepatocyte choice for bioartificial liver support systems. Liver Transpl (2001) 1.01
Effects of extracellular matrixes and growth factors on the hepatic differentiation of human embryonic stem cells. Am J Physiol Gastrointest Liver Physiol (2008) 1.00
One liver for four children: first clinical series of liver cell transplantation for severe neonatal urea cycle defects. Transplantation (2009) 0.99
Three-dimensional co-culture of primary human liver cells in bioreactors for in vitro drug studies: effects of the initial cell quality on the long-term maintenance of hepatocyte-specific functions. Altern Lab Anim (2002) 0.99
Primary human liver cells as source for modular extracorporeal liver support--a preliminary report. Int J Artif Organs (2002) 0.99
Differentiated properties of hepatocytes induced from pancreatic cells. Hepatology (2002) 0.98
Initial experience with the modified extracorporeal liver-assist device for patients with fulminant hepatic failure: system modifications and clinical impact. Transplantation (2002) 0.97
Use of indium-111-labeled hepatocytes to determine the biodistribution of transplanted hepatocytes through portal vein infusion. Clin Nucl Med (2000) 0.95
Prometheus--a new extracorporeal system for the treatment of liver failure. J Hepatol (2003) 0.95
Hepatocyte transplantation in man. Transplant Proc (1992) 0.95
The hepatic microvascular system in health and its response to toxicants. Anat Rec (Hoboken) (2008) 0.95
Stem cells in liver regeneration and therapy. Cell Tissue Res (2007) 0.95
Liver stem cells: a scientific and clinical perspective. J Gastroenterol Hepatol (2008) 0.94
Route of hepatocyte delivery affects hepatocyte engraftment in the spleen. Transplantation (2003) 0.94
Hepatic progenitor cells from adult human livers for cell transplantation. Gut (2008) 0.93
The use of stem cells in liver disease. Curr Opin Organ Transplant (2009) 0.92
Early experiences with a porcine hepatocyte-based bioartificial liver in acute hepatic failure patients. Int J Artif Organs (2002) 0.91
Cell-mediated rejection results in allograft loss after liver cell transplantation. Liver Transpl (2008) 0.91
Safety observations in phase I clinical evaluation of the Excorp Medical Bioartificial Liver Support System after the first four patients. ASAIO J (2001) 0.91
The possible use of stem cells in regenerative medicine: dream or reality? Langenbecks Arch Surg (2009) 0.90
Human monocyte-derived neohepatocytes: a promising alternative to primary human hepatocytes for autologous cell therapy. Transplantation (2005) 0.90
Efficacy of an extracorporeal flat-plate bioartificial liver in treating fulminant hepatic failure. J Surg Res (2003) 0.90
Bioartificial liver systems: why, what, whither? Regen Med (2008) 0.90
Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science (2014) 5.47
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol (2013) 3.00
A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology (2003) 2.40
Hepatocyte-specific Smad7 expression attenuates TGF-beta-mediated fibrogenesis and protects against liver damage. Gastroenterology (2008) 2.07
GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am J Pathol (2009) 1.54
Hyperinsulinemia reduces osteoblast activity in vitro via upregulation of TGF-β. J Mol Med (Berl) (2012) 1.50
Myristoylated PreS1-domain of the hepatitis B virus L-protein mediates specific binding to differentiated hepatocytes. Hepatology (2013) 1.49
Toxicogenomics directory of chemically exposed human hepatocytes. Arch Toxicol (2014) 1.43
Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. Cancer (2007) 1.33
Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. Biochem Biophys Res Commun (2008) 1.23
IL-22-mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression in vitro. Am J Physiol Gastrointest Liver Physiol (2007) 1.21
Porcine endogenous retroviruses: no infection in patients treated with a bioreactor based on porcine liver cells. J Clin Virol (2003) 1.20
Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells. Cell Res (2009) 1.20
Time course of primary liver cell reorganization in three-dimensional high-density bioreactors for extracorporeal liver support: an immunohistochemical and ultrastructural study. Tissue Eng (2004) 1.18
Expression of fatty acid synthase in nonalcoholic fatty liver disease. Int J Clin Exp Pathol (2010) 1.18
Determinants of morbidity and survival after elective non-curative resection of stage IV colon and rectal cancer. Int J Colorectal Dis (2009) 1.16
Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma. Oncol Rep (2006) 1.14
Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. J Hepatol (2005) 1.13
DNA methylation of lipid-related genes affects blood lipid levels. Circ Cardiovasc Genet (2015) 1.12
HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Hepatology (2006) 1.12
Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma. Clin Cancer Res (2008) 1.08
Use of primary human liver cells originating from discarded grafts in a bioreactor for liver support therapy and the prospects of culturing adult liver stem cells in bioreactors: a morphologic study. Transplantation (2003) 1.08
Bone morphogenetic protein 4 is induced in hepatocellular carcinoma by hypoxia and promotes tumour progression. J Pathol (2009) 1.08
Hepatocyte polarization is essential for the productive entry of the hepatitis B virus. Hepatology (2011) 1.06
Down-regulation of methylthioadenosine phosphorylase (MTAP) induces progression of hepatocellular carcinoma via accumulation of 5'-deoxy-5'-methylthioadenosine (MTA). Am J Pathol (2011) 1.04
Cell characterization by proteome profiling applied to primary hepatocytes and hepatocyte cell lines Hep-G2 and Hep-3B. J Proteome Res (2010) 1.02
Profiling induction of cytochrome p450 enzyme activity by statins using a new liquid chromatography-tandem mass spectrometry cocktail assay in human hepatocytes. Drug Metab Dispos (2010) 1.02
Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes. Cancer Res (2003) 1.02
TGF-beta enhances alcohol dependent hepatocyte damage via down-regulation of alcohol dehydrogenase I. J Hepatol (2010) 1.01
Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone [corrected] proteins in human-derived hepatoblastoma cells. PLoS One (2013) 1.01
Three-dimensional perfusion bioreactor culture supports differentiation of human fetal liver cells. Tissue Eng Part A (2010) 1.00
Efficient human fetal liver cell isolation protocol based on vascular perfusion for liver cell-based therapy and case report on cell transplantation. Liver Transpl (2012) 1.00
Three-dimensional co-culture of primary human liver cells in bioreactors for in vitro drug studies: effects of the initial cell quality on the long-term maintenance of hepatocyte-specific functions. Altern Lab Anim (2002) 0.99
Construction of large signaling pathways using an adaptive perturbation approach with phosphoproteomic data. Mol Biosyst (2012) 0.99
Hepatitis B virus induces expression of antioxidant response element-regulated genes by activation of Nrf2. J Biol Chem (2010) 0.99
Direct transcriptional regulation of human hepatic cytochrome P450 3A4 (CYP3A4) by peroxisome proliferator-activated receptor alpha (PPARα). Mol Pharmacol (2013) 0.99
In vitro differentiated adult human liver progenitor cells display mature hepatic metabolic functions: a potential tool for in vitro pharmacotoxicological testing. Cell Transplant (2010) 0.98
Multifunctional mesoporous silica-coated graphene nanosheet used for chemo-photothermal synergistic targeted therapy of glioma. J Am Chem Soc (2013) 0.98
Cellular damage to human hepatocytes through repeated application of 5-aminolevulinic acid. J Hepatol (2003) 0.97
Mouse fetal liver cells in artificial capillary beds in three-dimensional four-compartment bioreactors. Am J Pathol (2005) 0.97
HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro. J Pharmacol Toxicol Methods (2010) 0.96
Adiponectin-stimulated CXCL8 release in primary human hepatocytes is regulated by ERK1/ERK2, p38 MAPK, NF-kappaB, and STAT3 signaling pathways. Am J Physiol Gastrointest Liver Physiol (2009) 0.95
Aldehyde oxidase 1 is highly abundant in hepatic steatosis and is downregulated by adiponectin and fenofibric acid in hepatocytes in vitro. Biochem Biophys Res Commun (2006) 0.95
Human tissue for in vitro research as an alternative to animal experiments: a charitable "honest broker" model to fulfil ethical and legal regulations and to protect research participants. Altern Lab Anim (2006) 0.95
Xanthohumol, a chalcon derived from hops, inhibits hepatic inflammation and fibrosis. Mol Nutr Food Res (2010) 0.95
TIP47 plays a crucial role in the life cycle of hepatitis C virus. J Hepatol (2013) 0.95
Comparative analysis of phase I and II enzyme activities in 5 hepatic cell lines identifies Huh-7 and HCC-T cells with the highest potential to study drug metabolism. Arch Toxicol (2011) 0.95
Does hepatic steatosis affect drug metabolizing enzymes in the liver? Curr Drug Metab (2011) 0.95
Inhibition of the IFN-beta response in hepatocellular carcinoma by alternative spliced isoform of IFN regulatory factor-3. Mol Ther (2008) 0.94
Scaling down of a clinical three-dimensional perfusion multicompartment hollow fiber liver bioreactor developed for extracorporeal liver support to an analytical scale device useful for hepatic pharmacological in vitro studies. Tissue Eng Part C Methods (2011) 0.94
Chemerin is highly expressed in hepatocytes and is induced in non-alcoholic steatohepatitis liver. Exp Mol Pathol (2013) 0.94
State-of-the-art of 3D cultures (organs-on-a-chip) in safety testing and pathophysiology. ALTEX (2014) 0.94
Repression of cytochrome P450 activity in human hepatocytes in vitro by a novel hepatotrophic factor, augmenter of liver regeneration. J Pharmacol Exp Ther (2005) 0.93
Dynamic 3D culture promotes spontaneous embryonic stem cell differentiation in vitro. Tissue Eng Part C Methods (2010) 0.93
Human precision-cut liver tumor slices as a tumor patient-individual predictive test system for oncolytic measles vaccine viruses. Int J Oncol (2009) 0.92
Impact of perioperative allogeneic red blood cell transfusion on recurrence and overall survival after resection of colorectal liver metastases. Dis Colon Rectum (2015) 0.91
Combined logical and data-driven models for linking signalling pathways to cellular response. BMC Syst Biol (2011) 0.91
Compartmental hollow fiber capillary membrane-based bioreactor technology for in vitro studies on red blood cell lineage direction of hematopoietic stem cells. Tissue Eng Part C Methods (2011) 0.91
RNA stability in human liver: comparison of different processing times, temperatures and methods. Mol Biotechnol (2013) 0.91
Disruption of the Smad7 gene enhances CCI4-dependent liver damage and fibrogenesis in mice. J Cell Mol Med (2008) 0.91
Bioartificial liver systems: why, what, whither? Regen Med (2008) 0.90
Adiponectin and its receptors in rodent models of fatty liver disease and liver cirrhosis. World J Gastroenterol (2006) 0.90
Regulation of polyamine synthesis in human hepatocytes by hepatotrophic factor augmenter of liver regeneration. Biochem Biophys Res Commun (2006) 0.89
Chronic CCl4 intoxication causes liver and bone damage similar to the human pathology of hepatic osteodystrophy: a mouse model to analyse the liver-bone axis. Arch Toxicol (2014) 0.89
L-carnosine inhibits high-glucose-mediated matrix accumulation in human mesangial cells by interfering with TGF-β production and signalling. Nephrol Dial Transplant (2011) 0.89
Nrf2 activates augmenter of liver regeneration (ALR) via antioxidant response element and links oxidative stress to liver regeneration. Mol Med (2013) 0.89
Isolation and characterization of adult human liver progenitors from ischemic liver tissue derived from therapeutic hepatectomies. Tissue Eng Part A (2009) 0.89
Combining theoretical analysis and experimental data generation reveals IRF9 as a crucial factor for accelerating interferon α-induced early antiviral signalling. FEBS J (2010) 0.89
High molecular weight adiponectin reduces apolipoprotein B and E release in human hepatocytes. Biochem Biophys Res Commun (2006) 0.89
Active ammonia transport and excretory nitrogen metabolism in the climbing perch, Anabas testudineus, during 4 days of emersion or 10 minutes of forced exercise on land. J Exp Biol (2006) 0.88
BH3-only proteins Mcl-1 and Bim as well as endonuclease G are targeted in spongistatin 1-induced apoptosis in breast cancer cells. Mol Cancer Ther (2009) 0.88
Isolation of human hepatocytes by a two-step collagenase perfusion procedure. J Vis Exp (2013) 0.88
Extracorporeal liver support based on primary human liver cells and albumin dialysis--treatment of a patient with primary graft non-function. J Hepatol (2003) 0.88
P60-c-src suppresses apoptosis through inhibition of caspase 8 activation in hepatoma cells, but not in primary hepatocytes. J Hepatol (2006) 0.87
Carbon tetrachloride-induced liver damage in asialoglycoprotein receptor-deficient mice. Biochem Pharmacol (2009) 0.87
Relationship between oxidative stress and hepatic glutathione levels in ethanol-mediated apoptosis of polarized hepatic cells. World J Gastroenterol (2009) 0.87
Evaluation and optimization of hepatocyte culture media factors by design of experiments (DoE) methodology. Cytotechnology (2008) 0.87
Kaempferol, a new nutrition-derived pan-inhibitor of human histone deacetylases. J Nutr Biochem (2012) 0.87
Human hepatocytes: isolation, culture, and quality procedures. Methods Mol Biol (2012) 0.87
Excimer laser channel creation in polyethersulfone hollow fibers for compartmentalized in vitro neuronal cell culture scaffolds. Acta Biomater (2007) 0.86
Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents. Mol Cancer (2010) 0.86
Augmenter of liver regeneration (ALR) protects human hepatocytes against apoptosis. Biochem Biophys Res Commun (2010) 0.86
Liver resection in the elderly: significance of comorbidities and blood loss. J Gastrointest Surg (2014) 0.86
MMP-9 activity is increased by adiponectin in primary human hepatocytes but even negatively correlates with serum adiponectin in a rodent model of non-alcoholic steatohepatitis. Exp Mol Pathol (2011) 0.85
Evaluation of primary human liver cells in bioreactor cultures for extracorporeal liver support on the basis of urea production. Artif Organs (2006) 0.85